Immunology
Personalized cancer vaccines now possible due to discovery of cancer frameshift neoantigens
Researchers from Arizona State University's Biodesign Institute demonstrated experimental proof-of-concept that cancer mutations produce individual neoantigens, or newly formed antigens, and can be used for cancer vaccines. The new paper published in Scientific Reports on October 2, shows that neoantigens can be used to protect against cancer.  Discuss
New synthetic vaccine fights infectious disease with assistance from the data cloud
A new synthetic vaccine developed by researchers at the University of Bristol and the French National Centre for Scientific Research can be stored at warmer temperatures due to an engineered scaffold design. The details of the Chikungunya vaccine candidate are published in Science Advances on September 25.  Discuss
Vaccine in development against hypervirulent Klebsiella
Concerns arising over the development of hypervirulent strains of Klebsiella pneumoniae have led researchers to develop an entirely new vaccine to protect against the gram-negative bacteria. A team of researchers at Washington University School of Medicine in St. Louis and VaxNewMo (a startup based in St. Louis) designed the vaccine by genetically manipulating E. coli. The details of the prototype designed were published in the Proceedings of the National Academy of Sciences on August 27th.  Discuss
Thermally stable TB vaccine may now be possible thanks to an innovative new process
Researchers at the University of Bath have developed a process that protects vaccines from heat damage by trapping them in silica cages. The results were published in Scientific Reports on August 8, 2019. Using a leading candidate in the development on new vaccines, Ag85b in conjunction with adjuvant Sbi-Ag85b, thermal stability of tested using a novel process called ensilication.  Discuss
Structure-based vaccine design may help save the lives of infants and children
A new experimental vaccine, utilizing structure-based design, shows promise in a phase I clinical trial. The vaccine will protect against respiratory syncytial virus (RSV), a leading cause of infectious disease deaths in infants. Researchers at the University of Texas at Austin published findings on Aug 2, 2019 in Science stating that one dose elicited increases in RSV-neutralizing antibodies over several months.  Discuss
1
Conferences
11th Annual PEGS Europe
November 18-22
Lisbon Portugal
Antibody Engineering & Therapeutics
December 9-13
San Diego, California United States
Society for Laboratory Automation and Screening (SLAS) 2020
January 25-29, 2020
San Diego, California United States
American Society for Microbiology (ASM) Biothreats
January 28-30, 2020
Arlington, Virginia United States
Festival of Genomics 2020
January 29-30, 2020
London, Greater London United Kingdom
General Discussion
Topic Replies / Views Last Update
Consumers' Preference to Buy Unlabeled Produce Increases after Exposure to GMO-labeled Pro
by Mahesh Gupta
0 / 9 More than 3 days ago
by Mahesh Gupta
Super-precise new CRISPR tool could tackle a plethora of genetic diseases
by Mahesh Gupta
0 / 12 More than 3 days ago
by Mahesh Gupta
Tech Overview – Thin Layer Chromatography
by Thin film coatings, Material Science
0 / 4 More than 3 days ago
by optics
Making the leap from academia to industry
by Cindy
0 / 27 More than 3 days ago
by Cindy
14% of Global Food Goes to Waste, FAO Reports
by Mahesh Gupta
0 / 6 More than 3 days ago
by Mahesh Gupta
To see more posts from our community or to share a post of your own, go to our community's forum page.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter